In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patient Voice To Data: How Novartis Is Listening Up, Harnessing RWE In APMA

Executive Summary

Physician-turned-pharma executive, Iris Zemzoum, leads Novartis in the Asia Pacific, Middle East and Africa (APMA) region. She explains how the Swiss group is empowering patients to help shape the future of health care and also partnering across the diverse region to leverage real-world evidence.

You may also be interested in...



Canada Publishes Real World Evidence Guidance For HTA And Regulatory Decision Making

The new guidance was drawn up through extensive engagement with national and international experts in RWD and RWE, as well as stakeholders in Canada.

Novartis’ Bouchard On Delivering Personalized Cancer Medicine In Asia Pacific, Middle East, Africa

Francis Bouchard, Region Head for AMACO (Asia Pacific, Middle East and Africa Countries), Novartis Oncology, discusses a range of issues around mainstreaming personalized/precision oncology therapies such as Kymriah in the region, including reimbursement systems, partnerships and digital initiatives.

Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value

A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV148584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel